PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026
NEW YORK, Dec. 28, 2017 /PRNewswire/ -- PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026
Read the full report: https://www.reportlinker.com/p05257607
Summary
Alzheimer's disease (AD) is a looming endangerment to global health, and a threat to the world economy. One in every three seniors in the US dies with AD or another form of dementia. It is the sixth leading overall cause of death in the US, and ranks as the fifth leading cause of death among those aged 65 years old or older. The overall costs of AD were estimated to reach upwards of $259B in 2017 in the US alone, $175B (68%) of which was paid for by Medicaid or Medicare. The government spending on AD is expected to rise sharply across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) due to the aging global population.
During 2016-2026, the growth of the AD market will be driven by the entry of disease-modifying therapies (DMTs), including the passive immunotherapies aducanumab, gantenerumab, and crenezumab, which will have significant uptake in the US, the 5EU (France, Germany, Italy, Spain, and UK), and Japan. In addition to DMTs, novel symptomatic therapies with innovative mechanisms of action are anticipated to become routinely used in care over the 10-year forecast period.
The major drivers of growth in the AD market in the 7MM over the forecast period include -
- Entry of DMTs, including the passive immunotherapies aducanumab, gantenerumab, and crenezumab, and the beta-secretase (BACE) inhibitors verubecestat and lanabecestat.
- Entry of novel symptomatic therapies such as intepirdine.
- Entry of DMTs targeting presymptomatic AD population: CAD106, CNP520, and JNJ-54861911.
- Rising prevalence of AD and MCI.
- Expanding diagnostic capability.
- Growing social awareness of the disease.
In 2016, it is estimated that the global AD market had reached around $2.9B across the 7MM. By the end of the forecast period in 2026, sales across these markets will reach about $14.8B, increasing at a Compound Annual Growth Rate (CAGR) of 17.5% over the 10-year forecast period, which will see the launch of 20 new therapies, including several drug candidates that have the potential to modify the underlying cause of the disease.
The report "PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026", providesoverview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
In depth, this report provides the following -
- Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
- Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
- Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report:AB Science, Abbvie, AC Immune, Acadia, Actinogen Medical, Adamas Pharmaceuticals, Allergan, Amgen, Archer Pharmaceuticals
Scope
- Overview of AD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
- Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
- Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: https://www.reportlinker.com/p05257607
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article